Strategic collaboration aims to improve early diagnosis
Category: News
The drug was recently approved in the US for familial chylomicronaemia syndrome
Brekiya is now the first DHE auto-injector to be approved by the regulator
Regulator confirms safety and efficacy of new treatment option for patient
Biotech spin-off targets fibrosis, neoplasm and neovascularization
Aspire-FTD study aims to stop disease progression with one-time treatment
Trial progresses towards topline data expected later in the year
FDA recognises KER-0193 as a potential therapy for rare paediatric disease
Screening begins for study evaluating LTI-03 in idiopathic pulmonary fibrosi
Private equity firm Apiary Capital backs rapid growth of performance-i